World Health Organization advises against remdesivir for coronavirus treatment, Europe News & Top Stories

World Health Organization advises against remdesivir for coronavirus treatment, Europe News & Top Stories

"The fact that it was an antiviral that showed some benefit in certain trials - but not in all trials - was enough to push people to want to use it because we had no tools, but I do think it probably will be supplanted shortly", Adalja said, adding that the indication for drugs can change over time.

A World Health Organization (WHO) expert panel has advised against the use of the antiviral drug remdesivir for patients admitted to hospital with COVID-19, regardless of how severely ill they are, because there is now no evidence that it improves survival or the need for ventilation.

The WHO's Guideline Development Group (GDG) panel said its recommendation was based on an evidence review that included data from four worldwide randomised trials involving more than 7,000 patients hospitalised with COVID-19. The drug is approved in some countries for the treatment of COVID-19. It includes data from four global randomized trials involving over 7,000 patients hospitalized for Covid-19.

According to World Health Organization, there is now no evidence that the drug improves survival or reduces the need for ventilation.

The FDA originally granted emergency use authorization to remdesivir in May.

Gilead has questioned the results of WHO's trial and said the agency still has not released key data to allow the company or others to evaluate the reliability of the interim results.

Biden denounces 'irresponsible' Trump fight to reverse election
In Arizona , a judge was set to decide on a Republican push to block the certification of election results for the state. If we don't have access to all this data , it is going to put us behind the eight ball by a matter of a month or more.

Publishing updated treatment guidance in the BMJ medical journal, the panel acknowledged that their recommendation does not mean that remdesivir has no benefit for patients.

The recommendation against remdesivir was based on data from four randomized trials including 7,333 people hospitalized with Covid-19. The European Commission granted the drug conditional authorization in July based on the US -led clinical trial.

The United States, the European Union and other countries have granted temporary approval for the use of remdesivir after initial research showed it may shorten recovery time in some coronavirus patients.

It also said that evidence review found that the drug is costly and complex to administer and has very little efficacy.

The WHO noted that the evidence did not prove that remdesivir has no benefit but rather, there is no evidence based on now available data that it does improve important patient outcomes.

The antiviral is one of only two medicines now authorized to treat Covid-19 patients across the world. Trump repeatedly touted the drug early in the pandemic, though medical evidence was lacking to support his claims.

Related Articles